Vimarsana
Biggest News Aggregation in the World

Page 6 - Cell Surface News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Surface. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Surface Today - Breaking & Trending Today

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Vimarsana News

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Multiple epcoritamab (DuoBody-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line

Historic Ford's Theatre announces 2022/23 season - Vimarsana News

Historic Ford's Theatre announces 2022/23 season

Lineup to include Horton Foote’s ‘The Trip to Bountiful' and Cheryl L. West’s new musical about rock ‘n’ roll trailblazer Sister Rosetta Tharpe.

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses - Vimarsana News

AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress - Vimarsana News

Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress

Multiple epcoritamab (DuoBody-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial - Vimarsana News

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial

Company AnnouncementBased on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next stepsData from the clinical trial to be presented at a future medical meetingLarge B-cell lymphoma (LBCL) is a common form of non-Hodgkin’s lymphoma (NHL...